Abbott’s Amplatzer Amulet shows promise in atrial fibrillation trial
Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) occluder for…
Cardiovascular
-
-
Boston Scientific reports outcomes from trial of LAAC device
Boston Scientific has reported positive three-year data from the OPTION global trial of the WATCHMAN FLX left atrial appendage closure…
-
Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a…
-
Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib
Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat…
-
Penumbra reveals positive data for algorithm-assisted thrombectomy tech
Penumbra has posted positive data for its computer-assisted vacuum thrombectomy (CAVT) technology aimed at treating patients with intermediate-risk pulmonary embolism…
-
Abbott touts long-term efficacy for dissolvable Esprit BTK stent
Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral…
-
J&J’s Shockwave deal pays off as IVL catheter meets primary endpoint in trial
Johnson & Johnson’s (J&J) Shockwave Medical unit has reported that its Javelin peripheral intravascular lithotripsy (IVL) catheter system successfully met…
-
Boston Scientific to bolster cardiac ablation portfolio with Cortex acquisition
Boston Scientific has signed a definitive agreement for the acquisition of an Ajax Health company, Cortex, to bolster its cardiac ablation…
-
Johnson & Johnson MedTech concludes enrolment for OMNY-AF trial pilot phase
Johnson & Johnson MedTech has concluded subject enrolment for the pilot phase of the OMNY-AF study of the investigational OMNYPULSE…
-
Abbott starts new trial to assess early use benefit of HeartMate 3
Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit from early advanced therapy…
